- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00614562
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bern, Switzerland, 3010
- Department of Intensive Care Medicine, University Hospital - Inselspital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject itself or its next of kin has given written informed consent
- Independent physician has given written informed consent
- Male or female patients aged 18 - 80 years (extremes included).
- Mechanical ventilation for ≥ 48 hours prior to enrolment
- Presence of Critical Illness Polyneuropathy / Polymyopathy (CIP/M) according to the MRC Scale for Muscle Examination in 12 Muscle groups (Table 1) with or without loss of sensibility and muscle reflexes.
Presence of at least one of the following risk factors (A - D) known to be associated with CIP/M. Note, the risk factor does not need to be present at enrolment but needs to have been present prior to enrolment during the actual stay in the ICU:
A: severe sepsis defined as the presence of an infection is highly suspected or proven and three or more of the following systemic inflammatory response syndrome (SIRS) criteria are met (Bernard et al 2001 s. Figure 15):
- core temperature greater than 38 degrees celsius (100.4 degrees F) or less than 36 degrees celsius (96.8 degrees F);
- heart rate greater than 90 beats per minute;
- respiratory rate greater than 20 breaths per minute, or arterial carbon dioxide tension (Paco2) greater than 32 mm Hg, or mechanical ventilation for an acute process;
- a white cell count of more than 12 000/mm3 or less than 4000/mm3 , or a differential count showing more than 10% immature neutrophils.
- B: MODS (s. Figure 15)
- C: treatment with corticosteroids for at least 24 hours (either as repeated bolus or as continuous infusion).
- D: treatment with neuro-muscular blocking agents for at least 24 hours (either as repeated bolus or as continuous infusion).
Exclusion Criteria:
- Patient is less than 18 years or more than 80 years of age
- The attending physician refuses to allow enrollment
- The patient refuses informed consent
- Next of kin is unavailable or refuses informed consent
- The independent physician refuses informed consent
- Pregnant or breast-feeding female. A pregnancy test will be performed in all female patients less than 60 years of age
- Any contraindication to insertion/exchange a nasogastric tube, including (but not limited to): severe oropharyngeal malformation or bleeding; esophageal varices, tumor, infection, stenosis, or rupture, bleeding disorder with evidence of active bleeding.
- Presence or suspicion of diaphragm injury
- Presence or suspicion of a central nervous system (CNS) proximal of the spinal cord level C2) including (but not limited to): infarction, bleeding, tumor, or infection in the CNS
- Presence or suspicion of any preexisting peripheral neuromuscular disorder.
- History of heart and/or lung transplantation
- Any mechanical cardiac assist device (excluding intraaortic balloon pump)
- Any contraindication to reduce sedation or to stop neuromuscular blockage in order to allow spontaneous breathing
- The patient needs to be ventilated with a mode of mechanical ventilation that targets a redefined tidal volume or airway pressure as per attending physician
- Severe hemodynamic instability as per attending physician
- A fraction of inspired oxygen (FiO2) of > 0.8 at enrollment.
- The patient currently participates in another interventional clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NAVA
|
NAVA for 72 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in mean inspiratory electrical activity of the diaphragm (Edi)
Time Frame: beginning to end of study
|
beginning to end of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in ventilatory and respiratory parameters Changes in sedative and vasoactive drugs used
Time Frame: beginning to end of study
|
beginning to end of study
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Sinderby C, Navalesi P, Beck J, Skrobik Y, Comtois N, Friberg S, Gottfried SB, Lindstrom L. Neural control of mechanical ventilation in respiratory failure. Nat Med. 1999 Dec;5(12):1433-6. doi: 10.1038/71012. No abstract available.
- Tuchscherer D, Z'graggen WJ, Passath C, Takala J, Sinderby C, Brander L. Neurally adjusted ventilatory assist in patients with critical illness-associated polyneuromyopathy. Intensive Care Med. 2011 Dec;37(12):1951-61. doi: 10.1007/s00134-011-2376-0. Epub 2011 Nov 3.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KEK BE 250/07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polyneuropathy
-
PfizerCompletedTransthyretin Amyloid Polyneuropathy (ATTR-PN)China
-
German Cancer Research CenterUniversity Hospital Heidelberg; National Center for Tumor Diseases, HeidelbergCompletedExercise | Chemotherapy-induced PolyneuropathyGermany
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedDiabetic Patients With PolyneuropathyNetherlands
-
NycomedCompletedSymptomatic Diabetic Peripheral PolyneuropathyDenmark
-
PfizerCompletedTransthyretin Familial Amyloid PolyneuropathyJapan
-
Peking University Third HospitalRecruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
University Health Network, TorontoCompleted
-
Eisai Inc.CompletedMild to Moderate Diabetic Sensorimotor PolyneuropathyUnited States
-
Vanderbilt UniversityUCB PharmaCompletedChronic Idiopathic Axonal PolyneuropathyUnited States
Clinical Trials on Neurally adjusted ventilatory assist (NAVA)
-
Boston Children's HospitalCompletedRespiratory FailureUnited States
-
University Hospital, GenevaUniversity of Lausanne Hospitals; University Hospital St Luc, Brussels; University... and other collaboratorsCompletedNeurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator InteractionNon Invasive Ventilation | Patient Ventilator InteractionBelgium, Switzerland
-
St. Justine's HospitalSunnybrook Health Sciences CentreCompletedRespiratory FailureCanada
-
University Hospital Inselspital, BerneCompleted
-
King's College Hospital NHS TrustKing's College London; Guy's and St Thomas' NHS Foundation Trust; National Institute... and other collaboratorsCompletedAdults With Cardiopulmonary Disease at Risk of Prolonged Weaning From Mechanical VentilationUnited Kingdom
-
Fraser HealthCompletedRespiratory Distress SyndromeCanada
-
King's College LondonKing's College Hospital NHS TrustCompletedBronchopulmonary DysplasiaUnited Kingdom
-
Hôpital Européen MarseilleCompletedChronic Obstructive Pulmonary DiseaseFrance
-
Hospital Universitario La PazUnknownPatient/Ventilator AsynchronySpain
-
Mount Sinai Hospital, CanadaRecruiting